The Preventing Effects of Lisinopril, Sildenafil and Combined Usage of Them on the Formation of Intra-Abdominal Adhesion

Yıl 2011, Cilt: 16 Sayı: 4, 167 - 169, 01.08.2011

Cüneyt Kırkıl Serdar Coşkun Nurullah Bülbüller Erhan Aygen Koray Karabulut

Öz

Objective: In this study, it was aimed to compare the effectiveness of lisinopril and sildenafil on the prevention of intra-abdominal adhesions and to investigate whether there was a synergistic effect if they were combined. Materials and Methods: Fourty rats divided into four groups and mesothelial damage created. No medication was given to rats in group 1, lisinopril (6.5 mg/kg/d) in group 2, sildenafil (0.8 mg/kg/d) in group 3, and lisinopril combined with sildenafil in group 4 were given to rats by gavage for 7 days. Then, abdominal cavities were reopened and adhesion scores were determined. Results: The mean intra-abdominal adhesion scores of groups were 2.3±0.5, 0.9±0.7, 0.6±0.8, and 0.7±0.9, respectively. The mean adhesion scores of all treatment groups were significantly lower than control group (p0.05,and group 3 vs group 4 p>0.5). Conclusion: : Lisinopril and sildenafil alone is effective in preventing the formation of intra-abdominal adhesions. Their combination does not increase their potencies.

Anahtar Kelimeler

-

Lisinopril, Sildenafil ve Birlikte Kullanımlarının Karın İçi Yapışıklık Oluşmasını Önleyici Etkileri

Öz

Amaç: Bu çalışmada lisinopril ve sildenafilin karın içi yapışıklıkları önlemedeki etkinliklerinin karşılaştırılması ve birlikte uygulanmaları halinde sinerjik etki gösterip göstermeyeceklerinin incelenmesi amaçlanmıştır. Gereç ve Yöntem: Kırk adet rat 4 gruba ayrılıp mezotel hasarı oluşturuldu. Birinci gruptaki ratlara her hangi bir ilaç verilmez iken 2. gruptakilere lisinopril (6.5 mg/kg/gün), 3. gruptakilere sildenafil (0.8 mg/kg/gün) ve 4. gruptakilere hem lisinopril hem de sildenafil gavaj yoluyla 7 gün verildi. Sonra karın boşluğu tekrar açılıp yapışıklık skorları belirlendi. Bulgular: Grupların ortalama karın içi yapışıklık skorları sırasıyla 2.3±0.5, 0.9±0.7, 0.6±0.8 ve 0.7±0.9 idi. Tüm tedavi gruplarının yapışıklık skorları kontrol grubununkinden belirgin olarak daha düşüktü (p0.05, grup 3 vs grup 4 p>0.5). Sonuç: Lisinopril ve sildenafil tek başlarına karın içi yapışıklık gelişmesini önlemede etkilidir. Birlikte kullanımları onların güçlerini artırmaz.

Anahtar Kelimeler

Yapışıklık, Lisinopril, Sildenafil

Kaynakça

• Morgan HE, Baker KM. Cardiac hypertrophy. Mechanical, neural, and endocrine dependence. Circulation 1991; 83: 13- 25.
• Wolf G, Haberstroh U, Neilson EG. Angiotensin II stimulates the proliferation and biosynthesis of type I collagen in cultured murine mesengial cells. Am J Pathol 1992; 140: 95-107.
• Brilla CG, Maisch B, Weber KT. Renin-angiotensin system and myocardial collagen matrix remodeling in hypertansive heart disease. In vivo and in vitro studies on collagen matrix regulation. Coin Invest 1993; 71: 35-41.
• Weber KT, Sun Y, Tyagi SC, Clentjens JP. Collagen network of the myocardium: function, structural remodeling and regulatory mechanisms. J Mol Cell Cardiol 1994; 26: 279-292.
• Marshall RP, McAnulty RJ, Laurent GJ. Angiotensin II is mitogenic for human lung fibroblasts via activation of the type I receptor. Am J Respir Crit Care Med 2000; 161: 1999-2004.
• Mezzano SA, Ruiz-Ortega M, Egido J. Angiotensin II and renal fibrosis. Hypertension 2001; 38: 635-638.
• Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesengial cells. J Clin Invest 1994; 93: 2431-2437.
• Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994; 331: 1286-1292.
• Roberts AR. Transforming growth factor-b: Activity and efficacy in animal models of wound healing. Wound Repair Regeneration 1995; 3: 408-418.
• Williams RS, Rossi AM, Chegini N, Schultz G. Effect of transforming growth factor β on postoperative adhesion formation and intact peritoneum. J Surg Res 1992; 52: 65-70.
• Chegini N. The role of growth factors in peritoneal healing: Transforming growth factor beta (TGF-beta). Eur J Surg 1997; 577: 17-23.
• Lucas PA, Warejcka DJ, Young HE, Lee BY. Formation of abdominal adhesions is inhibited by antibodies to transforming growth factor-β1. J Surg Res 1996; 65: 135-138.
• Zhang H, Pakeerappa P, Lee HJ, Fisher SA. Induction of PDE5 and de-sensitization to endogenous NO signaling in a systemic resistance artery under altered blood flow. J Mol Cell Cardiol 2009; 47: 57-65.
• Colle I, De Vriese, Van Vlierberghe H, Lamerie NH, De Vos M. Systemic and splanchnic haemodynamic effects of sildenafil in an in vivo animal model of cirrhosis support for a risk in cirrotic patients. Liver Int 2004; 24: 63-68.
• Sirotkin AV, Makarevich AV, Pivko J, Kotwica J, Genieser H, Bulla J. Effect of cGMP analogues and protein kinase G blocker on secretory activity, apoptosis and the cAMP/protein kinase A system in porcine ovarian granulosa cells in vitro. J Steroid Biochem Mol Biol 2000; 74: 1–9.
• Redondo J, Bishop JE,Wilkins MR. Effect of atrial natriuretic peptide and cyclic GMP phosphodiesterase inhibition on collagen synthesis by adult cardiac fibroblasts. Br J Pharmacol 1998; 124: 1455–1462.
• Ayten R, Cetinkaya Z, Girgin M,Ozercan I, Ustundag B, Aygen E. The effects of intraperitoneal sildenafil administration on healing of left colonic anastomoses and intra-abdominal adhesion formation in the presence of intra- abdominal infection. Dis Colon Rectum 2008; 51: 1837-1841.
• Joannides R, Bizet-Nafeh C, Costentin A et al. Chronic ACE inhibition enhances the endothelial control of arterial mechanics and flow-dependent vasodilatation in heart failure. Hypertension 2001; 38: 1446–1450.
• Katz SD, Balidemaj K, Homma S,Wu H, Wang J, Maybaum S. Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol 2000; 36: 845–851.
• Hryniewicz K, Dimayuga C, Hudaihed A, et al. Inhibition of angiotesin-converting enzyme and phosphodiesterase type 5 improves endothelial function in heart failure. Clin Sci 2005; 108: 331-338.
• Gönderilme Tarihi: 25.04.2011